Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Osilodrostat in Hepatic Impairment
NCT02372084Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osilodrostat in Cushing's syndrome, sponsored by Novartis. Primary endpoints: Area Under the Concentration-time Curve from Time Zero to the Last Measurable Concentration at 96 hours, Area Under the Concentration-time Curve from Time Zero to Infinity at 96 hours and 4 more. Started Apr 2015; status: completed.
02
Drugs
osilodrostat
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT02372084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02372084.